FDA staff involved in review of Sanofi and Regeneron's PCSK9 inhibitor alirocumab for reducing LDL-cholesterol.
You may also be interested in...
Sanofi and Regeneron's 'extended negotiations' with FDA on requirements would later apply to Amgen's Repatha.
MedWatch report of hepatotoxicity prompted two 'urgent information requests' to sponsors a month before alirocumab user fee goal date.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.